- Home
- DXYZ vs RGNX Comparison
DXYZ vs RGNX Comparison
Compare DXYZ & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXYZ
- RGNX
- Stock Information
- Founded
- DXYZ N/A
- RGNX 2008
- Country
- DXYZ
- RGNX United States
- Employees
- DXYZ N/A
- RGNX N/A
- Industry
- DXYZ
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DXYZ
- RGNX Health Care
- Exchange
- DXYZ Nasdaq
- RGNX Nasdaq
- Market Cap
- DXYZ 471.9M
- RGNX 387.0M
- IPO Year
- DXYZ 2024
- RGNX 2015
- Fundamental
- Price
- DXYZ $37.05
- RGNX $8.50
- Analyst Decision
- DXYZ
- RGNX Strong Buy
- Analyst Count
- DXYZ 0
- RGNX 8
- Target Price
- DXYZ N/A
- RGNX $31.75
- AVG Volume (30 Days)
- DXYZ N/A
- RGNX 1.2M
- Earning Date
- DXYZ N/A
- RGNX 07-31-2025
- Dividend Yield
- DXYZ N/A
- RGNX N/A
- EPS Growth
- DXYZ N/A
- RGNX N/A
- EPS
- DXYZ N/A
- RGNX N/A
- Revenue
- DXYZ N/A
- RGNX $156,718,000.00
- Revenue This Year
- DXYZ N/A
- RGNX $327.08
- Revenue Next Year
- DXYZ N/A
- RGNX N/A
- P/E Ratio
- DXYZ N/A
- RGNX N/A
- Revenue Growth
- DXYZ N/A
- RGNX 80.70
- 52 Week Low
- DXYZ N/A
- RGNX $5.04
- 52 Week High
- DXYZ N/A
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- DXYZ N/A
- RGNX 45.12
- Support Level
- DXYZ N/A
- RGNX $8.41
- Resistance Level
- DXYZ N/A
- RGNX $10.64
- Average True Range (ATR)
- DXYZ 0.00
- RGNX 0.89
- MACD
- DXYZ 0.00
- RGNX -0.19
- Stochastic Oscillator
- DXYZ 0.00
- RGNX 20.33
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.